GE Ventures, Stanford launch digital health company

GE Ventures and Stanford Health Care have partnered to launch Evidation Health, an independent company committed to improving health outcomes with evidence-based digital medicine.

Focused on generating real-world clinical and economic evidence for digital health products and platforms,

Evidation Health will focus on generating real-world clinical and economic evidence for digital health products and platforms by combining health outcomes data with new approaches to predictive analytics to identify and deploy the most effective and efficient patient management strategies and interventions, according to a release.

"Our company has the core capabilities to make precision digital medicine a reality," said Deborah Kilpatrick, the new company's CEO. "We envision a digital health-enabled future where clinical interventions can be customized and concentrated in ways that maximize clinical and economic benefit for payers, providers and, most importantly, patients."

To accelerate commercial progress, Evidation Health joined forces with The Activity Exchange, a digital health company with strong predictive analytics capabilities, and closed its Series A financing in January of 2015. The round was led by GE Ventures, with participation from Asset Management Ventures and Rock Health. The company is focused on forging new partnerships while continuing its corporate and academic collaborations with organizations including Humana, Biogen Idec., Sanofi, Harvard Business School and Wharton Business School.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.